Machine Learning-Assisted Iterative Screening for Efficient Detection of Drug Discovery Starting Points.

Journal: Journal of medicinal chemistry
Published Date:

Abstract

High-throughput screening (HTS) remains central to small molecule lead discovery, but increasing assay complexity challenges the screening of large compound libraries. While retrospective studies have assessed active-learning-guided screening, extensive prospective validations are rare. Here, we report the first prospective evaluation of machine learning (ML)-assisted iterative HTS in a large-scale drug discovery project. Using a mass spectrometry-based assay for salt-inducible kinase 2, we screened just 5.9% of a two million-compound library in three batches and recovered 43.3% of all primary actives identified in a parallel full HTS─including all but one compound series selected by medicinal chemists. This demonstrates that ML-guided iterative screening can significantly reduce the experimental cost while maintaining hit discovery quality. Retrospective benchmarks further showed that the ML approach outperforms similarity-based methods in hit recovery and chemical space coverage. In summary, this study highlights the potential of ML-driven iterative HTS to improve efficiency also in large-scale drug discovery projects.

Authors

  • Alex T Müller
    Swiss Federal Institute of Technology (ETH), Department of Chemistry and Applied Biosciences, Vladimir-Prelog-Weg 4, CH-8093, Zurich, Switzerland.
  • Markus Hierl
    Pharma Research and Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Dominik Heer
    Pharma Research and Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Paul Westwood
    Pharma Research and Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Philippe Hartz
    Pharma Research and Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Bigna Wörsdörfer
    Pharma Research and Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Christian Kramer
    Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck , Innrain 82, 6020 Innsbruck, Austria.
  • Wolfgang Haap
    Pharma Research and Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Doris Roth
    Pharma Research and Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Michael Reutlinger
    F. Hoffmann-La Roche Ltd., pRED, Pharma Research & Early Development, Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.

Keywords

No keywords available for this article.